Melissa Louise Hartman, LCSW-C, LCADC-S | |
1892 Eastfields Way, Edgewood, MD 21040-3114 | |
(443) 527-9900 | |
Not Available |
Full Name | Melissa Louise Hartman |
---|---|
Gender | Female |
Speciality | Social Worker - Clinical |
Location | 1892 Eastfields Way, Edgewood, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1902451842 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | 21195 (Maryland) | Primary |
Mailing Address | Practice Location Address |
---|---|
Melissa Louise Hartman, LCSW-C, LCADC-S 1892 Eastfields Way, Edgewood, MD 21040-3114 Ph: (443) 527-9900 | Melissa Louise Hartman, LCSW-C, LCADC-S 1892 Eastfields Way, Edgewood, MD 21040-3114 Ph: (443) 527-9900 |
News Archive
The price of prescription medicines will not rise as a result of the Free Trade Agreement with the United States. The Australian Government gave this undertaking going into the negotiations and has delivered on this commitment.
The case of Sen. Edward Kennedy (D-Mass.), who has been diagnosed with brain cancer, is "identical from a regulatory standpoint to the plight of hundreds of thousands of other Americans" and "shouts to the heavens the humane necessity of urgent reform in the drug approval process to make it work better for people who have serious and terminal diseases," according to a Wall Street Journal opinion piece by Steven Walker and Ronald Trowbridge, chief adviser and adjunct scholar, respectively, of the Abigail Alliance for Better Access to Developmental Drugs.
Sinapis Pharma is pleased to announce that it has received notice from the FDA that its Investigational New Drug application (IND) for the use of IV methamphetamine for acute stroke was approved on April 9, 2010. "We have accomplished a great deal of work for a small company on a very tight budget. We have GMP drug ready for the Phase I clinical trial and the Phase I site is prepared to begin this protocol," said Dr. Donald Picker , the company CEO.
Cellectar, Inc., a privately held radiopharmaceuticals company that designs and develops products to detect, treat and monitor human cancers, has announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for its (131)I-CLR1404 drug candidate for testing in patients with advanced solid malignancies.
› Verified 3 days ago
Kim Bennett-selby, LCSW-C Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1331 Charlestown Dr, Edgewood, MD 21040 Phone: 443-928-9554 |